Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK inhibitors from Regor for the treatment of breast cancer. Regor will receive an upfront cash payment of $850 million and is eligible to receive additional cash payments. Genentech will be responsible for clinical development, manufacturing and commercialization.
Regor Pharmaceuticals USA is part of Regor Therapeutics Group, a clinical-stage biotechnology company developing clinically differentiated medicines to address large unmet needs in oncology, metabolism and auto-immunity.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.